Skip to main content

Table 1 Baseline demographic, clinical and laboratory variables for patients with and without available QoL data

From: Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study

  

All patients

Available QoL

Missing QoL

All patients

Variable

Class

N

%

N

%

N

%

P

Age

≤65

353

57

138

55

215

58

 
 

>65

267

43

111

45

156

42

0.2900

Gender

Male

367

59

151

61

216

58

 
 

Female

252

41

98

39

154

42

0.5739

PS

0

333

54

122

49

211

57

 
 

1

239

38

110

44

129

35

 
 

2

48

8

17

7

31

8

0.0611

Number of sites

1

354

58

147

59

207

57

 
 

>1

260

42

102

41

158

43

0.5672

Liver involvement

No

149

24

52

21

97

27

 
 

Yes

460

76

197

79

263

73

0.0872

Metastases

Synchronous

415

68

168

68

247

68

 
 

Metachronous

196

32

80

32

116

32

0.9374

Adjuvant chemotherapy

No

488

79

200

81

288

78

 
 

Yes

130

21

48

19

82

22

0.4013

Tumour site

Colon

398

64

160

64

238

64

 
 

Rectum

211

34

86

35

125

35

 
 

both

11

2

3

1

8

1

0.6730

LDH

≤1xULN

380

61

134

56

246

66

 
 

>1xULN

240

39

115

44

125

34

0.0017

ALP

≤1xULN

350

56

129

52

221

60

 
 

>1xULN

270

44

120

48

150

40

0.0560

CEA

≤1xULN

177

28

61

25

116

31

 
 

>1xULN

443

72

188

75

255

69

0.0673

EuroQoL

        

Mobility

1

223

81

223

81

   
 

2-3

54

19

54

19

   

Self-care

1

255

93

255

93

   
 

2-3

19

7

19

7

   

Usual activities

1

193

71

193

71

   
 

2-3

79

29

79

29

   

Pain/discomfort

1

137

50

137

50

   
 

2-3

138

50

138

50

   

Anxiety/depression

1

145

53

145

53

   
 

2-3

130

47

130

47

   

VAS score

  

70 [10–100] **

   
  1. ** Median (range).
  2. ULN= Upper Limit of Normal.
  3. VAS= visual analogue scale.
  4. PS= performance status.
  5. ALP= alkaline phosphatase.
  6. LDH= serum lactate dehydrogenase.